8-K: Stoke Therapeutics Reports Q3 2025 Results, Advances Zorevunersen

Stoke Therapeutics announced its third quarter 2025 financial results and provided updates on its clinical programs, including significant progress in the Phase 3 EMPEROR study for Dravet syndrome.

Summary

• Net loss for the three months ended September 30, 2025, was $38.3 million, or $0.65 per share, compared to a net loss of $26.4 million, or $0.47 per share, for the same period in 2024.
• Net income for the nine months ended September 30, 2025, was $51.0 million, or $0.85 per diluted share, compared to a net loss of $78.5 million, or $1.48 per share, for the same period in 2024.
• As of September 30, 2025, the company had $328.6 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to mid-2028.
• The global Phase 3 EMPEROR study for zorevunersen in Dravet syndrome is actively recruiting patients in the U.S., UK, and Japan, with over 20 patients randomized and approximately 35 additional patients in the screening period.
• The EMPEROR study is on track to complete enrollment in the second half of 2026.
• New two-year data from zorevunersen showed continuing improvements in cognition and behavior in Dravet syndrome patients, contrasting with natural history study findings.
• Three-year safety and efficacy data from open-label extension studies showed durable reductions in major motor seizure frequency and continuing improvements in cognition and behavior, with zorevunersen generally well tolerated.
• A meeting with the FDA is scheduled before year-end 2025 to review four years of safety and efficacy data and discuss potential expedited regulatory pathways under Breakthrough Therapy Designation.
• Patient recruitment for the Phase 1 OSPREY study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) is underway in the UK, with European sites expected to activate in early 2026.
• Lead optimization is underway to identify a clinical candidate for the treatment of SYNGAP1 in 2026.
• Ian F. Smith was appointed Chief Executive Officer in October 2025, after serving as Interim CEO since March 2025.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical trial progress for its lead candidate, a solid financial runway, and significant year-to-date financial improvements, despite increased quarterly losses due to R&D and launch readiness investments. The appointment of a permanent CEO and pipeline expansion further contribute to a very positive outlook.

Positives

• Strong cash, cash equivalents, and marketable securities totaling $328.6 million as of September 30, 2025, anticipated to fund operations to mid-2028.
• Significant progress in the global Phase 3 EMPEROR study for zorevunersen, with more than 20 patients randomized and 35 additional patients in screening within three months of initiation.
• Positive two-year clinical data for zorevunersen demonstrating continuing improvements in cognition and behavior in Dravet syndrome patients.
• Durable reductions in major motor seizure frequency and continued improvements in cognition and behavior observed over three years in open-label extension studies for zorevunersen.
• Zorevunersen was generally well tolerated across studies to date with no new safety findings.
• Scheduled meeting with the FDA before year-end 2025 under Breakthrough Therapy Designation to discuss potential expedited regulatory pathways for zorevunersen.
• Initiation of patient recruitment for the Phase 1 OSPREY study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA).
• Substantial increase in year-to-date 2025 revenue to $183.0 million from $13.9 million in the same period 2024, primarily driven by Biogen and Acadia agreements.
• Shift from a net loss of $78.5 million in YTD 2024 to a net income of $51.0 million in YTD 2025.
• Appointment of Ian F. Smith as permanent Chief Executive Officer, providing leadership stability.

Negatives

• Net loss for the third quarter of 2025 increased to $38.3 million from $26.4 million in the third quarter of 2024.
• Research and development expenses increased to $37.7 million in Q3 2025 from $22.2 million in Q3 2024, driven by zorevunersen advancement.
• Sales, general and administrative expenses increased to $16.0 million in Q3 2025 from $12.7 million in Q3 2024, driven by personnel and launch readiness expenses.

Risks

• Ability to advance, obtain regulatory approval for, and ultimately commercialize product candidates.
• Risk that partners (Biogen, Acadia) could breach or terminate their collaboration, leading to a loss of anticipated financial or other benefits.
• Possibility that the company and Biogen may not be successful in their development of zorevunersen and that, even if successful, they may be unable to successfully commercialize zorevunersen.
• Risk that positive results in a clinical trial may not be replicated in subsequent trials or that successes in early-stage clinical trials may not be predictive of results in later-stage trials.
• Other risks and uncertainties described under the heading 'Risk Factors' in the company's Annual Report on Form 10-K for the year ended December 31, 2024, its quarterly reports on Form 10-Q, and other SEC filings.

Future Outlook

The company anticipates completing enrollment for the global Phase 3 EMPEROR study in the second half of 2026. A critical meeting with the FDA is planned before year-end 2025 to discuss expedited regulatory pathways for zorevunersen. European sites for the STK-002 OSPREY study are expected to activate in early 2026, and lead optimization for a SYNGAP1 clinical candidate is underway for 2026. The strong financial position is expected to fund operations to mid-2028, supporting continued investment in pipeline expansion and commercialization readiness.

Management Comments

• "Stokes progress in 2025 has the Company on an important growth trajectory. We are creating an understanding of the devastating impacts of Dravet syndrome on peoples lives and the potential of zorevunersen to improve outcomes for them through substantial seizure reductions and improvements in cognition and behavior."
• "In just three months since the initiation of our Phase 3 EMPEROR study, we have made significant progress with more than 20 patients randomized into dosing and a steady progression of more patients entering the screening period."
• "At the same time, presentations of new clinical data at medical congresses have provided greater understanding of zorevunersens disease-modifying potential that is highly differentiated from any currently available treatments."
• "We look forward to meeting with the FDA under our Breakthrough Therapy Designation before year-end, at which time we will review the four years of safety and efficacy data from our clinical studies and discuss how we can work together to deliver zorevunersen to patients through expedited regulatory pathways."
• "Our strong financial position is allowing us to invest in the business, including enhancing our internal capabilities to rapidly scale in preparation for potential commercialization, while also expanding our pipeline in the areas of ADOA and SYNGAP1 as well as broadening our research activities."

Industry Context

Stoke Therapeutics operates in the highly specialized and high-risk biotechnology sector, focusing on rare genetic neurological and ophthalmic diseases. The development of RNA medicines, specifically antisense oligonucleotides (ASOs), represents a cutting-edge approach to restoring protein expression. The progress in the Phase 3 EMPEROR study for Dravet syndrome, a severe epileptic encephalopathy, positions zorevunersen as a potential first-in-class disease-modifying treatment, which could be a significant advancement in a field where current treatments primarily manage symptoms. The expansion into ADOA and SYNGAP1 further diversifies its rare disease pipeline, aligning with a broader industry trend of targeting specific genetic causes of disease. The collaboration with Biogen for zorevunersen commercialization outside North America is a common strategy for smaller biotech firms to leverage larger partners' global reach.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks.
• Zorevunersen's disease-modifying potential is highlighted as "highly differentiated from any currently available treatments" for Dravet syndrome, suggesting a potentially superior profile compared to existing standard-of-care anti-seizure medicines.
• The progress of a Phase 3 study for a rare disease, coupled with Breakthrough Therapy Designation, indicates a significant advancement within the rare disease drug development landscape, where many programs often face high attrition rates in earlier stages.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong cash position, significant clinical progress, potential for expedited regulatory pathways, and improved year-to-date financial performance. Recent share sales provided capital but also resulted in some dilution.
• Patients (Dravet syndrome): Highly positive impact due to promising clinical data for zorevunersen showing disease-modifying potential, seizure reduction, and improvements in cognition/behavior, offering hope for a new treatment.
• Patients (ADOA, SYNGAP1): Positive impact due to pipeline expansion and initiation of clinical studies for STK-002 and lead optimization for SYNGAP1.
• Employees: Positive impact due to company growth, investment in internal capabilities, and launch readiness expenses, suggesting job stability and potential for expansion.
• Regulatory Authorities (FDA, EMA): Continued engagement through Breakthrough Therapy Designation and planned meetings to discuss expedited pathways.
• Partners (Biogen, Acadia): Continued collaboration and progress in development activities.

Next Steps

• Present new data from the zorevunersen clinical development program at the American Epilepsy Society (AES) 2025 Annual Meeting, December 5-9, in Atlanta, Georgia.
• Meet with the FDA before year-end 2025 to review safety and efficacy data and discuss expedited regulatory pathways for zorevunersen.
• Activate European sites for the Phase 1 OSPREY study of STK-002 in early 2026.
• Initiate European sites for the global Phase 3 EMPEROR study in the first half of 2026.
• Identify a clinical candidate for the treatment of SYNGAP1 in 2026.
• Complete enrollment for the global Phase 3 EMPEROR study in the second half of 2026.
• Continue investing in internal capabilities to rapidly scale in preparation for potential commercialization.
• Expand the pipeline in the areas of ADOA and SYNGAP1, and broaden research activities.

Key Dates

Recommendation

The company has reported significant positive clinical trial advancements for its lead candidate, zorevunersen, including durable efficacy and safety data, and is on track for a critical FDA meeting under Breakthrough Therapy Designation. The strong cash position provides a long runway, and the year-to-date financial performance shows a substantial turnaround to net income, driven by strategic agreements. While quarterly losses increased due to R&D and launch readiness, these are considered necessary investments in future growth. The progress across the pipeline and stable management leadership indicate strong operational execution and future potential, making it a compelling investment.

Keywords

Dravet syndrome, zorevunersen, STK-002, Autosomal Dominant Optic Atrophy, ADOA, SYNGAP1, biotechnology, RNA medicine, antisense oligonucleotide, ASO, clinical trials, Phase 3, EMPEROR study, OSPREY study, financial results, STOK, rare disease, neurology, ophthalmology